Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK has doubts on UPC but commits to SPCs

Executive Summary

The UK’s participation in Europe’s unified patent court (UPC) hangs in the balance in the event of no deal being reached on the UK’s ‘Brexit’ departure from the European Union (EU) in March 2019, according to guidance issued by the UK government on intellectual-property (IP) issues relating to pharmaceuticals, including patents and supplementary protection certificates (SPCs). But even with no deal, the UK will continue to offer SPCs.

You may also be interested in...



Germany Remains In The Dark On UPC Implementation

With a constitutional challenge still pending in Germany, and lingering uncertainties over Brexit, Germany's federal government appears to have little idea when a planned European Unified Patent Court could come into effect.

Germany Remains In The Dark On UPC Implementation

With a constitutional challenge still pending in Germany, and lingering uncertainties over Brexit, Germany’s federal government appears to have little idea when a planned European unified patent court could come into effect. 

No-Deal Brexit May Lead To A Fragmented Market

Panellists at the UK’s Westminster Health Forum conference on Biosimilars in the NHS united over concerns of a no-deal Brexit and what it would mean for generics and biosimilars producers.

Topics

UsernamePublicRestriction

Register

GB001293

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel